Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

21st.Bio raises $97 million for manufacturing site

by Matt Blois
January 2, 2022 | A version of this story appeared in Volume 100, Issue 1

 

The Danish biotech start-up 21st.Bio has raised $97 million to build its first manufacturing site. The company helps clients choose the best organism to produce a desired chemical and then optimizes the strain for large-scale production. 21st.Bio is based on technology from the Danish biotech company Novozymes, which has a stake in the firm and could earn royalties on products made by 21st.Bio clients.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.